For female cancer survivors, premature ovarian insufficiency (POI) is a common complication of anticancer treatments. Ovarian tissue cryopreservation before treatment, followed by auto-transplantation after remission is a promising option to restore fertility and ovarian endocrine function. However, auto-transplantation is associated with the risk of reintroducing malignant cells harbored in the stroma of the ovarian autograft. To mitigate this risk, we investigated in this pilot study whether an immuno-isolating dual-layered poly(ethylene glycol)(PEG) capsule can retain cancer cells, while supporting folliculogenesis. The dual PEG capsule loaded with 1000 4T1 cancer cells retained 100% of the encapsulated cells in vitro for 21 days of culture. However, a greater cell load of 10,000 cells/capsule led to capsule failure and cells' release. To assess the ability of the capsule to retain cancer cells, prevent metastasis, and support folliculogenesis in vivo we co-encapsulated cancer cells with ovarian tissue in the dual PEG capsule and implanted subcutaneously in mice. Control mice implanted with 2000 non-encapsulated cancer cells had tumors formed within 14 days and metastasis to the lungs. In contrast, no tumor mass formation or metastasis to the lungs was observed in mice with the same number of cancer cells encapsulated in the capsule. Our findings suggest that the immuno-isolating capsule may prevent the escape of the malignant cells potentially harbored in ovarian allografts and, in the future, improve the safety of ovarian tissue autotransplantation in female cancer survivors.
INTRODUCTION
Premature ovarian insufficiency (POI) is a common complication of anticancer treatments, such as chemo-and radio-therapy, due to ovarian sensitivity to these treatments [1, 2] . In recent years, the survival rate of children with cancer has increased to over 85% due to the development of modern anticancer therapies; however, these patients experience longterm health problems far after they're cancer-free [3, 4] . Female cancer survivors with POI suffer from sterility and a myriad of problems associated with ovarian hormone deficiencies, such as premature osteopenia, muscle wasting, and cardiovascular disease [5] . Fertility preservation options, such as oocyte and embryo cryopreservation, are available for post-pubertal adolescent girls and young women. However, these options are not available for prepubertal patients [6] .
For prepubertal patients, an experimental option of cryopreservation of ovarian tissue before exposure to toxic treatments, and subsequent auto-implantation after remission would restore both fertility and ovarian endocrine function [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Ovarian tissue auto-transplantation has resulted in close to 100 births to date [18] . Importantly, ovarian tissue auto-transplantation is associated with a significant risk of re-introducing malignant cells harbored in the autologous transplant, particularly in the case of hematologic malignancies, which is common in children [14, [19] [20] [21] . A few patient cases of ovarian auto-transplantation in Europe resulted in relapse and multiple experiments in mice further confirmed the risks associated with this approach [19] [20] [21] [22] . A potential option for these patients that would minimize the risk of cancer re-introduction is allotransplantation of donor ovarian tissue [23] [24] [25] , however this option would solely provide ovarian endocrine function restoration and not provide an option for biologic fertility preservation.
To date, there is no standard universal protocol to ensure the absence of malignant cells in ovarian autografts removed from the patient prior to anti-cancer treatments. Several groups attempted to identify and quantify cancerous cells present in ovarian tissue using histology or PCR [19, 21, 22] . However, challenges in identifying cancer cells harbored in the tissue prevent clinical translation of this approach, especially in the case of hematologic malignancies, such as acute lymphoblastic leukemia, acute myeloid leukemia, and non-Hodgkin's lymphoma, where ovarian involvement can be high. For example, even when histological analysis showed no evidence of malignant cells, an increase in cancer biological Regen Med Front. 2019;1:e190006. https://doi.org/10.20900/rmf20190006
Regenerative Medicine Frontiers 3 of 15 markers was shown through PCR analysis [19, 21, 22] . It's recommended that the use of molecular markers be used to detect malignant cells, because solely histology is not sufficient; however, not all cancers display specific genetic markers that can be detected via PCR making tissue characterization very difficult [26] . Additionally, there is no consensus as to which markers are most sufficient to detect malignant cells present in ovarian tissue, dependent on the strain of cancer [22] , further complicating the classification of the ovarian tissue as safe.
We hypothesized that immuno-isolation may mitigate the risk of reintroducing malignant cells during ovarian tissue auto-transplantation.
Immuno-isolation uses a semi-permeable membrane to encapsulate foreign allogeneic tissue and allow free diffusion of nutrients and metabolites, while preventing the infiltration of immune cells attenuating the immune response. Previously, we have shown that an immunoisolating multilayered poly(ethylene glycol)(PEG) capsule supports ovarian tissue in vivo and did not elicit a measurable inflammatory response [25, 27] . The immuno-isolating capsule contains a degradable core that is conducive for ovarian tissue survival and a non-degradable shell, which acts as the immunoprotective barrier. We have demonstrated that allogeneic ovarian tissue does not elicit a host immune response when encapsulated in the Dual PEG capsule, and the capsule prevents lymphocytic infiltration, allowing for allogeneic transplantation of ovarian tissue. Because the immuno-isolating capsule prevents infiltration of immune cells from the host towards the allograft through the barrier, we hypothesized that the capsule will contain cancer cells harbored in the ovarian tissue and will prevent their escape. Thus, encapsulating ovarian autografts in the immuno-isolating capsule mitigates the risk of cancer relapse or metastasis. Here, we investigated the ability of the immunoisolating capsule to prevent spreading of the cancer cells in vitro and in vivo, preventing tumor mass formation and metastasis, while maintaining the function of ovarian tissue. Balb/c derived 4T1 breast cancer cells originate from an invasive cancer line and were chosen to investigate the effectiveness of the capsule to retain cancerous cells and detect metastasis in a scenario when cancer cells escape the capsule and invade the host.
This work aims to mitigate the risk of ovarian tissue auto-transplantation and provide female cancer survivors experiencing POI with safer options to restore fertility and hormonal balance. and 0.1% N-vinyl-2-pyrrolidone (Sigma-Aldrich, St. Louis, USA). The detailed protocol is described in Day et al. [25] . 
MATERIALS AND METHODS

Gel Preparation
Collection of Murine Donor Ovaries
4T1 Cell and Ovarian Tissue Encapsulation
BALB/c derived 4T1 cancer cells were encapsulated at a concentration of 250,000 cells/mL (1000 cells/gel) or 2.5 million cell/mL (10,000 cells/gel).
For encapsulation in the PEG-MT, the cancer cells and/or ovarian tissue were transferred into a 4 μL droplet of the plasmin sensitive tri-functional peptide and PEG-VS precursors' solution. The droplet was allowed to crosslink for 5 minutes and then was quenched in maintenance media.
For Dual PEG hydrogel encapsulation, the tissue was first encapsulated in a 4 μL PEG-MT hydrogel and was then placed in the center of a 10 μL bead of PEG-VS precursor solution (5% w/v PEG-VS, .4% Irgacure 2959, 0.1% NVP) and exposed to UV light [16] . All constructs were imaged immediately after encapsulation of the cells and tissue to verify complete encapsulation. 
Subcutaneous Injection and Implantation
Tumor, Gel, and Organ Collection
At the time of sacrifice, tumors or gels were collected, imaged via IVIS, and fixed in Bouin's fixative. Additionally, the brain, liver, lungs, spleen, blood, and ovaries were collected, imaged via IVIS, and fixed in Bouin's fixative.
Histological Analysis of Retrieved Capsules and the Encapsulated
Ovarian Tissue
Following sacrifice, the immuno-isolating devices were retrieved from mice, fixed in Bouin's fixative at 4 °C overnight, transferred and stored in 70% ethanol at 4 °C. After processing, samples were embedded in paraffin, serially sectioned at 5 μm thickness, and stained with hematoxylin and eosin. With the inclusion of the non-degradable shell in the case of Dual PEG, cell escape out of the capsule significantly decreased (p < 0.05). Dual PEG gels with 1000 cells encapsulated in its core showed 0% escape through 21 days culture ( Figure 1D-H) . When the cell concentration was increased and 10,000 cells were encapsulated in PEG-Dual, cells did escape with 80% of gels showing some extent of cell escape by day 21. However, the kinetics of cell escape was attenuated compared to PEG-MT, as at day 2, 100% of Dual PEG gels containing 10,000 retained the cells in the core and at day 6, 80% showed complete retention ( Figure 1H ). This demonstrated that the inclusion of the non-degradable shell greatly hinders cell migration and proliferation out of the gel, leading to the retention of cells in the capsule through 21 days in vitro culture.
Statistics
RESULTS
Encapsulation of Cancer Cells in Dual PEG Prevents Cancer Cell
Escape in Culture
Encapsulation of Cancer Cells in Dual PEG Prevents Spreading and
Metastasis in Vivo
To evaluate the Dual PEG capsule's ability to retain cancerous cells in vivo, cells were co-encapsulated with mouse ovarian tissue and implanted subcutaneously in a BALB/c mouse model. The cancer cell line, mouse ovarian tissue, and recipient mouse strain were all the same to negate any possible immune response. Either, 1000 or 10,000 cells, were encapsulated in Dual PEG with 6-8 day old ovarian tissue (Figure 2A injected subcutaneously. When 2000 cells were injected, proliferation was exhibited in 5/5 mice with radiance increasing from 3.56 × 10 4 to 6.02 × 10 9 photons/sec from day 0 to 14 ( Figure 2C -E,O). By Day 14,  all mice had to be sacrificed as a tumor mass had formed on the dorsal side and ulceration started to occur ( Figure 3A) . In the mice receiving 20,000 non-encapsulated cancer cells, proliferation and tumor mass formation was observed in 4/5 mice ( Figure 2F-H,O) . Similar to the 2000 cell group, the mice exhibited ulceration by day 14 and had to be sacrificed. The cells proliferated as shown by the significant increase of radiance from day 0 to day 14 ( Figure 2O ). To confirm the extracted tumor masses were in fact the labeled 4T1 cells, bioluminescence imaging was used. All tumors exhibited bioluminescence indicating the mass was cancerous and derived from the injected 4T1 cells ( Figure 3B ). From IVIS imaging, it appeared that all cancer cells were retained within the capsule. To confirm, when hydrogels were extracted, the capsules as well as the surrounding tissue were imaged via bioluminescence and only the inner core of the hydrogels showed luminescent signal ( Figure 3E ).
Additionally, upon macroscopic evaluation, the hydrogels containing cancer cells and ovarian tissue looked exactly as they did when implanted on day 0 and no tumor mass was present ( Figure 3D ). For the mice receiving 10,000 cancer cells co-encapsulated with ovarian tissue in Dual PEG (2 devices, 20,000 cancer cells total per mouse), 4/5 mice demonstrated tumor formation as shown through a significant increase in radiance over the 28 day implantation period ( Figure 2L-O) . Upon extraction, a tumor mass localized to the hydrogels was evident as the hydrogel appeared cloudy in appearance (Supplementary Figure S1 ). However, although the 10,000 cancer cells proliferated over the 28 day implantation period, the cells remained localized to the hydrogel, as the hydrogel showed a high level of radiance, indicating the cancer cells were present within the capsule, itself (Supplementary Figure S1 ). Interestingly, a higher number of follicles were observed in the ovarian tissue encapsulated with 1000 cancer cells compared to 10,000 cells, which could be due to damage to ovarian tissue by the cancerous cells [28] .
Multiple primordial follicles are present in capsules with 1000 and 10,000 cancer cells ( Figure 4B,D) . However, auto-transplantation presents the patients with a risk of re-introducing malignant cells, as the ovarian tissue was resected before treatment leading to the possibility of malignant cells being stored in the stroma of the tissue. In hematological cases, which is a high percentage of childhood cancers, this risk and ovarian involvement is very high [14, [19] [20] [21] [22] . Previous studies have been conducted to identify cancerous cells present in resected ovarian tissue from cancer patients. Due to discrepancies in characterization methodology, molecular marker criteria, and tissue heterogeneity, no universal protocol has been established to characterize ovarian tissue as safe [19] [20] [21] [22] creating a risk of re-seeding malignant cells for female cancer survivors following ovarian tissue auto-transplantation.
This work describes a method to mitigate this risk by retaining cancerous cells in a capsule which is also conducive for ovarian tissue survival and development. Previously, we developed a multilayered immuno-isolating capsule, Dual PEG, which contains a degradable core that is conducive for ovarian tissue development and a non-degradable shell that acts as an immunoprotective barrier [25] . We demonstrated that when encapsulating allogeneic ovarian tissue and using an allogeneic Next, we tested the ability of Dual PEG to retain cancer cells and prevent tumor mass formation and metastasis in vivo in a syngeneic mouse model.
Previous studies have suspended 100-200 cancerous cells in a fibrin or alginate matrix, and when implanted into mice, did not reintroduce leukemic cell contamination [29, 30] . Here, we encapsulated BALB/c mouse ovarian tissue with BALB/c derived 4T1 cancer cells (1000 or 10,000 cells however, all the cells were maintained in the gel as indicated by the lack of cells in surrounding tissues and susceptible organs. Macroscopically, we were able to see the tumor mass within the gel itself and upon IVIS imaging, the hydrogel was shown to be the only entity that contained cancer cells. At a high cell density of 10,000 cells/capsule, the Dual PEG gel is able to retain those cells and prevent metastasis, unlike the nonencapsulated control. When the capsules were explanted and histological analysis was performed, we observed the presence of healthy primary and secondary follicles. This is vital to a successful encapsulation strategy for auto-transplantation, as this shows the tissue is capable of surviving within the capsule, potentially restoring fertility and ovarian endocrine function.
CONCLUSIONS
This work demonstrated the capability of using an immuno-isolating capsule to retain cancer cells that may be present in an ovarian tissue autograft. Previously, we have shown that Dual PEG can support ovarian tissue survival and development, leading to the restoration of ovarian Regen Med Front. 2019;1:e190006. https://doi.org/10.20900/rmf20190006 endocrine function. We have also demonstrated the capsule's ability to protect encapsulated ovarian tissue from an immune response. By using this capsule to encapsulate a patient's ovarian autograft, the risk of reintroducing malignant cells present in that tissue is mitigated. Given there is no protocol by which clinical investigators can be absolutely certain ovarian autografts do not contain cancerous cells, girls that had hematologic malignancies, and showed zero to a low concentration (250,000 cells/mL) of cancerous cells in their ovarian biopsy, could potentially use of an immuno-isolating capsule to decrease the risk of cancer re-introduction. Through this work, the option of autotransplantation is potentially safer, which, although experimental, is the only option for pre-pubescent female cancer survivors to retain, both, future fertility and ovarian endocrine function. Future work will be done to assess the ability of encapsulated mouse ovarian tissue to produce viable eggs once encapsulated in the Dual PEG capsule. To this end, developing new methods to create a capsule using alternatives to photopolymerization may be necessary. Limitations of this study include the use of mouse ovarian tissue and a short in vivo transplantation period.
For this reason, future studies encapsulating human ovarian tissue will be conducted to investigate the ability of the PEG capsules and other biocompatible materials to accommodate the large volumetric expansion of human follicles during development and the ability for capsule to support ovulation and corpus luteum formation.
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